The American College of Physicians (ACP) has recommended that adults aged 65 years or older receive updated 2025–2026 mRNA-based COVID-19 vaccines, according to February guidelines published in Annals ...

The company revised its plan to seek full approval for middle-aged adults and accelerated approval for seniors.

Moderna (MRNA) stock is in focus as BioNTech (BNTX) sues the biotech for allegedly violating patent linked to the rival shot developed with Pfizer (PFE). Read more here.

Ongoing studies indicate that maternal COVID-19 vaccinations do not have any significant impact on prenatal neurodevelopment.

BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...

Among women who never got sick, researchers found the shots appeared to improve vascular and immune health. For mothers with ...

WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to help fight tumors. People with advanced lung or skin ...

Moderna says its experimental mRNA influenza vaccine, mRNA-1010, showed more than 30% greater relative vaccine efficacy against influenza A than a licensed egg-based flu shot in a large Phase 3 trial ...

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

By Ahmed Aboulenein WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it ...